Navigation Links
Biopharm Insight’s Respiratory Disease Report Highlights Key Drugs Coming Up for Approval or in Late-Stage Development
Date:11/6/2013

Norwood, MA (PRWEB) November 06, 2013

BioPharm Insight’s Respiratory Disease Report covers key drugs in development in this competitive therapeutic sector. The report is based on primary research and interviews conducted with numerous physicians, investigators and key opinion leaders at the recent European Respiratory Society Annual Congress 2013 in Barcelona, Spain.

In discussing the Respiratory Disease Report, Kirsty Barnes, Biopharm Insight’s Editor EMEA, said, “The report is another example of why decision makers in pharmaceutical R&D or the investment side of drug development rely on BioPharm Insight’s independent investigative journalism, market analytics and key industry contacts to gain competitive insight.”

Some highlights and key takeaways from the report:

  •     Competitive landscape of LABA/LAMA combinations in development to treat COPD
  •     Novartis'combination drug Ultibro Breezhaler for chronic obstructive pulmonary disease (COPD) and US market outlook
  •     Forest and Almirall’s aclidinium bromide/formoterol combination
  •     Boehringer's Spiriva Respimat (tiotropium) mist inhaler in COPD
  •     In idiopathic pulmonary fibrosis (IPF), Novartis’ QAX576, an anti-IL-13 in Phase II development, has been quietly terminated
  •     In asthma, GlaxoSmithKline and partner Theravance are still considering their strategy to progress Breo Ellipta (fluticasone furoate/vilanterol) for US approval.
  •     In pulmonary arterial hypertension (PAH), Actelion will need to get experts engaged in the discussion on Opsumit’s (macitentan) EU pricing. EU approval decision is expected YE.
  •     Bayer is in the planning stages of a Phase IIIb study (RESPITE) evaluating riociguat in PAH for those patients insufficiently treated with phosphodiesterase-5 inhibitors.
  •     PTC Therapeutics' ataluren for cystic fibrosis caused by nonsense mutations (nmCF).

Subscribers to BioPharm Insight received the Respiratory Report on October 15.

Non-subscribers, download the report.

About BioPharm Insight

BioPharm Insight is part of Infinata, a Financial Times Group company, and a leading provider of business intelligence solutions which also include BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.

About Infinata, Inc.

Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Business Inquiries: Holly Burke, hburke[at]infinata[dot]com, 781-619-0131
Media Inquiries: Brenda Nashawaty, Brenda[at]nashawaty[dot]com, 617-688-3253

Read the full story at http://www.prweb.com/releases/2013/11/prweb11300052.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. BioPharm Systems Named to the 2012 Lead411 Technology 200 List
2. BioPharm Systems to Host Webinar on Using iHelp in Oracle’s Siebel Clinical Trial Management System
3. BioPharm Systems to Host Webinar on Clinical Trial Supply Management with Siebel CTMS
4. Nine Lives Media Names BioPharm Systems to the MSPmentor 501
5. BioPharm Systems Unveils Study Data Mapper to Simplify the Preparation and Reporting of Clinical Data
6. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at ReportsnReports.com
7. Therapure Biopharma Inc. Awarded US Government Contract for Development of Anti-Nerve Gas Agent
8. World Antibiotic Resistance Market Saw Big Changes in Last Five Years, According to Biopharm Reports Study Available at MarketPublishers.com
9. Mass Spectrometry Marketplace Discussed by Biopharm Reports in In-demand Research Study Available at MarketPublishers.com
10. Study says children exposed to tobacco smoke face long-term respiratory problems
11. Study shows antibiotic improves respiratory function in lung transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology: